Nebacumab

Nebacumab is a human IgM monoclonal antibody developed for the treatment of sepsis, specifically targeting Gram-negative bacterial infections. Its mechanism of action involves binding to the lipid A region of endotoxin (lipopolysaccharide/LPS) produced by Gram-negative bacteria. By neutralizing circulating endotoxins and reducing levels of pro-inflammatory cytokines such as tumor necrosis factor-alpha, it was intended to mitigate the excessive inflammatory response that leads to septic shock. Nebacumab was developed by Centocor and marketed under the brand name Centoxin in some European countries in 1991. However, clinical trials failed to demonstrate a reduction in mortality among septic patients, leading to its withdrawal from the market in 1993[1][3][5][6][7].

Brand names

Centoxin

Other names

HA-1AHA1AHA 1Anebacumab